BRAF mutations in advanced cancers: clinical characteristics and outcomes
about
Melanoma: oncogenic drivers and the immune systemBeyond BRAF: where next for melanoma therapy?Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyLong Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation.Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomasMelanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.Claudin-1 Expression Is Elevated in Colorectal Cancer Precursor Lesions Harboring the BRAF V600E Mutation.The molecular genomics of metastatic brain tumours.A framework for genomic biomarker actionability and its use in clinical decision makingColorectal cancers from distinct ancestral populations show variations in BRAF mutation frequencyEffect of BRAF mutational status on expression profiles in conventional papillary thyroid carcinomasAssessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas.BRAF gene: From human cancers to developmental syndromes.Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.Stabilization of HIF-2α induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model.Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanomaDirect targeting of MEK1/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth.PIK3CA mutations in advanced cancers: characteristics and outcomes.EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patientsThe distribution of BRAF gene fusions in solid tumors and response to targeted therapy.Microarray expression profiling identifies genes, including cytokines, and biofunctions, as diapedesis, associated with a brain metastasis from a papillary thyroid carcinoma.Good clinical and radiological response to BRAF inhibitor in patient with metastatic thin melanoma.Melanoma metastasis: new concepts and evolving paradigms.Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma.FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973.BRAF mutation in sporadic colorectal cancer and Lynch syndrome.Prevalence of BRAF and NRAS mutations in fast-growing melanomas.Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma.BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas.BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasis.Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by β-catenin activity.
P2860
Q26775598-980A739D-9427-4909-B357-BD934281B5B3Q27006853-74B04C0C-BA93-4E59-9E16-65BD9393958EQ27276774-A1E890E9-ED34-415D-BB31-EA442CF00167Q27853361-D9D5A32B-B1B6-462E-A97A-E61FAC490F13Q28484668-E3B78B8F-D468-469A-A447-B9FDEDBC8EF6Q33845387-F73F7B8B-EEA1-4B17-8B29-C88DE556A368Q34369345-EA0DD812-49C9-4189-9B55-CE62B33F45A1Q34499855-93263AD0-1D89-4183-9416-BE686325BAA1Q34781122-7F094E6D-159E-4704-A683-357DBE4EFE69Q34997425-00E3E212-FC17-4320-B2BD-CC68ED06D143Q35042608-E7C3B4A2-ADA3-4662-A270-F7215D8FAF40Q35535953-74CCD34A-E4CF-44C9-A1A3-66AE97165ED5Q35751428-538E0E60-8ADF-4E51-B6AC-AD4D5EE244A2Q35802430-1C2F43EC-4D00-4FF2-8827-936B63735F41Q35916658-0EA9B547-2B12-4D41-8045-C74552A2D41BQ36218573-16C3BD6F-DB13-405F-8594-023A038596A5Q36260662-012802DE-4E87-4DC9-A741-7CBB09831364Q36764374-57D85468-E80D-41EC-A1A8-D57B8F950FB6Q36816318-CF8620E0-FF68-4947-996B-1B187B59AED0Q36926111-CD210889-5D37-4AD9-AC73-4096CA6DE080Q36977414-8346A5C2-F420-4D8C-A98E-698C29E332DBQ37308973-99CB0124-72B8-4B85-9DC0-1CCB85BB928EQ37382508-225C2B53-4C12-4F6A-8D85-7C0ACFC711B4Q38022496-5B5F5188-B2F7-4019-8F6F-276250164870Q38111220-A02003FE-A3CA-4324-91C3-3355130188B0Q41874771-DE44B429-A85F-477E-90F6-60D7A931DAC8Q42250522-04E6D315-33BA-47D9-9E4C-46CFAE10E67CQ43688934-1217A3B2-E4A0-4C44-8B1C-69A4D40F7315Q43740727-DC18E489-05F1-48C3-9B7A-9AB7BAF87775Q47877598-56CE381C-EDDF-40C5-BA92-7CF943E7B6EFQ48474734-EDA5D6CA-CE71-48DE-A509-D938E070F250Q48656930-32502C5C-6E58-411F-811E-E37910EF3BCBQ50642659-CAD6C0F9-F61E-4FF6-B921-24987A4C985D
P2860
BRAF mutations in advanced cancers: clinical characteristics and outcomes
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
BRAF mutations in advanced cancers: clinical characteristics and outcomes
@ast
BRAF mutations in advanced cancers: clinical characteristics and outcomes
@en
BRAF mutations in advanced cancers: clinical characteristics and outcomes
@nl
type
label
BRAF mutations in advanced cancers: clinical characteristics and outcomes
@ast
BRAF mutations in advanced cancers: clinical characteristics and outcomes
@en
BRAF mutations in advanced cancers: clinical characteristics and outcomes
@nl
prefLabel
BRAF mutations in advanced cancers: clinical characteristics and outcomes
@ast
BRAF mutations in advanced cancers: clinical characteristics and outcomes
@en
BRAF mutations in advanced cancers: clinical characteristics and outcomes
@nl
P2093
P2860
P50
P1433
P1476
BRAF mutations in advanced cancers: clinical characteristics and outcomes
@en
P2093
David Hong
Gerald Falchook
Hazem El-Osta
P2860
P304
P356
10.1371/JOURNAL.PONE.0025806
P407
P577
2011-01-01T00:00:00Z